148 related articles for article (PubMed ID: 17565497)
1. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".
Flux G; Bardies M; Chiesa C; Monsieurs M; Savolainen S; Strand SE; Lassmann M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1699-700. PubMed ID: 17565497
[No Abstract] [Full Text] [Related]
2. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".
Brans B; Bodei L; Giammarile F; Linden O; Luster M; Oyen WJG; Tennvall J
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):772-786. PubMed ID: 17268773
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry?
Bardiès M; Buvat I
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):5-20. PubMed ID: 21386782
[No Abstract] [Full Text] [Related]
4. [Nuclear medicine in oncotherapy].
Pávics L; Besenyi Z
Magy Onkol; 2015 Sep; 59(3):193-7. PubMed ID: 26339908
[TBL] [Abstract][Full Text] [Related]
5. Iodine-131 and Iodine-131-Meta-iodobenzylguanidine Dosimetry in Cancer Therapy.
Flux G; Leek F; Gape P; Gear J; Taprogge J
Semin Nucl Med; 2022 Mar; 52(2):167-177. PubMed ID: 34961618
[TBL] [Abstract][Full Text] [Related]
6. Radionuclide therapy beyond radioiodine.
Gabriel M
Wien Med Wochenschr; 2012 Oct; 162(19-20):430-9. PubMed ID: 22815123
[TBL] [Abstract][Full Text] [Related]
7. [Guideline draft of appropriate use of 131I-MIBG for internal radiotherapy of neuroendocrine tumors].
Nakajo M; Yoshinaga K; Oriuchi N; Kinuya S; Yokoyama K; Yamaguchi T; ; ;
Kaku Igaku; 2008 Feb; 45(1):suppl 1-40. PubMed ID: 19594094
[TBL] [Abstract][Full Text] [Related]
8. Clinical applications of dosimetry for mIBG therapy.
Flux GD; Chittenden SJ; Saran F; Gaze MN
Q J Nucl Med Mol Imaging; 2011 Apr; 55(2):116-25. PubMed ID: 21386786
[TBL] [Abstract][Full Text] [Related]
9. Optimization of molecular radiotherapy with [131I]-meta Iodobenzylguanidine for high-risk neuroblastoma.
Gaze MN; Gains JE; Walker C; Bomanji JB
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):66-78. PubMed ID: 23474636
[TBL] [Abstract][Full Text] [Related]
10. Intraarterial 131I-MIBG therapy of neuroendocrine tumors with liver metastases.
Popp M; Strumpf A; Zöphel K; Stroszczynski C; Kotzerke J
Nuklearmedizin; 2010; 49(1):N2-3. PubMed ID: 20336828
[No Abstract] [Full Text] [Related]
11. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
Bomanji JB; Papathanasiou ND
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
[TBL] [Abstract][Full Text] [Related]
12. The current status of targeted radiotherapy in clinical practice.
Gaze MN
Phys Med Biol; 1996 Oct; 41(10):1895-903. PubMed ID: 8912369
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Simplified Blood Dose Protocols for the Estimation of the Maximum Tolerable Activity in Thyroid Cancer Patients Undergoing Radioiodine Therapy Using 124I.
Jentzen W; Bockisch A; Ruhlmann M
J Nucl Med; 2015 Jun; 56(6):832-8. PubMed ID: 25858042
[TBL] [Abstract][Full Text] [Related]
14. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
[TBL] [Abstract][Full Text] [Related]
15. Perspective: multimodality radionuclide therapy of progressive disseminated lymphoma and neuroendocrine tumors as a paradigm for cancer control.
Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):525-9. PubMed ID: 23062194
[No Abstract] [Full Text] [Related]
16. EANM enabling guide: how to improve the accessibility of clinical dosimetry.
Gear J; Stokke C; Terwinghe C; Gnesin S; Sandström M; Tran-Gia J; Cremonesi M; Cicone F; Verburg F; Hustinx R; Giovanella L; Herrmann K; Gabiña PM
Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1861-1868. PubMed ID: 37086275
[TBL] [Abstract][Full Text] [Related]
17. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy.
Hartmann Siantar CL; DeNardo GL; DeNardo SJ
J Nucl Med; 2003 Aug; 44(8):1322-9. PubMed ID: 12902424
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with (131)I-metaiodobenzylguanidine with implications for the activity to administer.
Mínguez P; Flux G; Genollá J; Guayambuco S; Delgado A; Fombellida JC; Sjögreen Gleisner K
Med Phys; 2015 Jul; 42(7):3969-78. PubMed ID: 26133597
[TBL] [Abstract][Full Text] [Related]
19. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
[TBL] [Abstract][Full Text] [Related]
20. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.
Sgouros G; Kolbert KS; Sheikh A; Pentlow KS; Mun EF; Barth A; Robbins RJ; Larson SM
J Nucl Med; 2004 Aug; 45(8):1366-72. PubMed ID: 15299063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
